½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1552746

¼¼°èÀÇ ¼ö¸·¿° Ä¡·á ½ÃÀå : »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2034³â)

Meningitis Treatment Market (Causative Organism: Bacterial, Viral, and Fungal; and Type of Treatment: Antibiotic Therapy and Adjunctive Therapy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Transparency Market Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 158 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼ö¸·¿° Ä¡·á ½ÃÀå - Á¶»ç ¹üÀ§

TMRÀÇ Á¶»ç º¸°í¼­ '¼ö¸·¿° Ä¡·á ¼¼°è ½ÃÀå'Àº 2024-2034³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ÁöÇ¥¿¡ ´ëÇÑ ±ÍÁßÇÑ ÅëÂû·ÂÀ» ¾ò±â À§ÇØ °ú°Å»Ó¸¸ ¾Æ´Ï¶ó ÇöÀçÀÇ ¼ºÀå µ¿Çâ°ú ±âȸ¿¡ ´ëÇؼ­µµ Á¶»ç ÇÏ°í ÀÖ½À´Ï´Ù. º» º¸°í¼­´Â 2024³âÀ» ±âÁسâ, 2034³âÀ» ¿¹Ãø³âÀ¸·Î, 2018-2034³â ¼¼°è ¼ö¸·¿° Ä¡·á ½ÃÀåÀÇ ¼öÀÍ°ú ¿¹ÃøÀ» Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ 2024-2034³â ¼¼°è ¼ö¸·¿° Ä¡·á ½ÃÀåÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR%)µµ Á¦°øÇÕ´Ï´Ù.

ÀÌ º¸°í¼­´Â ±¤¹üÀ§ÇÑ Á¶»ç¸¦ °ÅÃÄ ÀÛ¼ºµÇ¾ú½À´Ï´Ù. 1Â÷ Á¶»ç¿¡¼­ ºÐ¼®°¡´Â KOL(Key Opinion Leader), ¾÷°è ¸®´õ, ¿ÀÇǴϾð Á¦Á¶¾÷ü¿ÍÀÇ ÀÎÅͺ並 ½Ç½ÃÇß½À´Ï´Ù. 2Â÷ Á¶»ç¿¡¼­´Â ÁÖ¿ä ±â¾÷ÀÇ Á¦Ç° ÀÚ·á, ¿¬·Ê º¸°í¼­, º¸µµ ÀÚ·á, °ü·Ã ÀÚ·á µîÀ» ÂüÁ¶ÇÏ¿© ¼ö¸·¿° Ä¡·á ½ÃÀåÀ» ÃßÂûÇß½À´Ï´Ù.

½ÃÀå ÇöȲ
2023³â ½ÃÀå ±Ô¸ð 1¾ï 5,090¸¸ ´Þ·¯
2034³â ½ÃÀå ±Ô¸ð 2¾ï 3,480¸¸ ´Þ·¯
CAGR 4.1%

ÀÌ º¸°í¼­´Â ¼¼°è ¼ö¸·¿° Ä¡·á ½ÃÀå °æÀï ±¸µµ¸¦ Á¶»çÇß½À´Ï´Ù. ¼¼°èÀÇ ¼ö¸·¿° Ä¡·á ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷ÀÌ È®ÀÎµÇ°í °¢ ±â¾÷Àº ´Ù¾çÇÑ ¼Ó¼ºÀ¸·Î ÇÁ·ÎÆÄÀϸµµË´Ï´Ù. ±â¾÷ °³¿ä, À繫»óȲ, ÃÖ±Ù µ¿Çâ, SWOT µîÀÌ º» º¸°í¼­¿¡¼­ ¼Ò°³µÇ°í ÀÖ´Â ¼¼°èÀÇ ¼ö¸·¿° Ä¡·á ½ÃÀå¿¡¼­ÀÇ ±â¾÷ÀÇ ¼Ó¼ºÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå ÀüÁ¦Á¶°Ç°ú Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à: ¼¼°è ½ÃÀå

Á¦4Àå ½ÃÀå °³¿ä

  • ¼Ò°³
  • °³¿ä
  • ½ÃÀå ¿ªÇÐ
  • ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø, 2020-2034³â

Á¦5Àå ÁÖ¿ä ÀλçÀÌÆ®

  • ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®
  • ÁÖ¿ä Á¦Ç°/ºê·£µå ºÐ¼®
  • ÁÖ¿ä M&A
  • COVID-19¿¡ ÀÇÇÑ »ê¾÷¿¡ ´ëÇÑ ¿µÇâ

Á¦6Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ¿øÀÎ »ý¹°º°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú¡¤ ¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : ¿øÀÎ »ý¹°º°, 2020-2034³â
    • ¼¼±Õ¼º
    • ¹ÙÀÌ·¯½º¼º
    • Áø±Õ¼º
  • ½ÃÀåÀÇ ¸Å·Â: ¿øÀÎ »ý¹°º°

Á¦7Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Ä¡·á À¯Çüº°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú¡¤ ¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : Ä¡·á À¯Çüº°, 2020-2034³â
    • Ç×»ýÁ¦ ¿ä¹ý
    • º¸Á¶¿ä¹ý
  • ½ÃÀåÀÇ ¸Å·Â : Ä¡·á À¯Çüº°

Á¦8Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : ¹é½ÅÀ¯Çüº°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú¡¤ ¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : ¹é½ÅÀ¯Çüº°, 2020-2034³â
    • ¼ö¸·¿°±Õ °áÇÕ ¹é½Å
    • ¼ö¸·¿°±Õ ´Ù´çü ¹é½Å(MPSV4)
    • È¥ÇÕ ¹é½Å
  • ½ÃÀåÀÇ ¸Å·Â: ¹é½ÅÀ¯Çüº°

Á¦9Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : À¯Åë ä³Îº°

  • ¼Ò°³ ¹× Á¤ÀÇ
  • ÁÖ¿ä Á¶»ç °á°ú¡¤ ¹ßÀü
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø : À¯Åë ä³Îº°, 2020-2034³â
    • º´¿ø ¾à±¹
    • ¼Ò¸Å ¾à±¹
    • ¿Â¶óÀÎ ¾à±¹
  • ½ÃÀåÀÇ ¸Å·Â : À¯Åë ä³Îº°

Á¦10Àå ¼¼°è ½ÃÀå ºÐ¼®°ú ¿¹Ãø : Áö¿ªº°

  • ÁÖ¿ä Á¶»ç °á°ú
  • ½ÃÀå ¸ÅÃâ ¿¹Ãø :Áö¿ªº°, 2020-2034³â
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • ½ÃÀåÀÇ ¸Å·Â : Áö¿ªº°

Á¦11Àå ºÏ¹Ì ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦12Àå À¯·´ ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦13Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦14Àå ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦15Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå ºÐ¼®°ú ¿¹Ãø

Á¦16Àå °æÀï ±¸µµ

  • ½ÃÀå±â¾÷ - °æÀï ¸ÅÆ®¸¯½º(±â¾÷ Tier ¹× ±Ô¸ðº°)
  • ½ÃÀå Á¡À¯À² ºÐ¼® : ±â¾÷º°(2023)
  • ±â¾÷ ÇÁ·ÎÆÄÀÏ
    • Bio-med(P) Ltd.
    • Novartis AG
    • Nuron Biotech, Inc.
    • Pfizer Inc.
    • Baxter International Inc.
    • Merck & Co. Inc.
    • Sanofi SA
    • GSK PLC
    • F. Hoffmann-Roche AG
    • Athlone Laboratories Limited
    • Wockhardt
JHS 24.10.10

Meningitis Treatment Market - Scope of Report

TMR's report on the global meningitis treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global meningitis treatment market for the period 2018-2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global meningitis treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the meningitis treatment market.

Market Snapshot
Market Value in 2023US$ 150.9 Mn
Market Value in 2034US$ 234.8 Mn
CAGR4.1%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global meningitis treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global meningitis treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global meningitis treatment market.

The report delves into the competitive landscape of the global meningitis treatment market. Key players operating in the global meningitis treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global meningitis treatment market profiled in this report.

Key Questions Answered in Global meningitis treatment Market Report:

  • What is the sales/revenue generated by meningitis treatment across all regions during the forecast period?
  • What are the opportunities in the global meningitis treatment market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2034?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Meningitis Treatment Market - Research Objectives and Research Approach

The comprehensive report on the global meningitis treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global meningitis treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global meningitis treatment market.

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Meningitis Treatment Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Product Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Meningitis Treatment Market Analysis and Forecast, 2020-2034

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. Key Product/Brand Analysis
  • 5.3. Key Mergers & Acquisitions
  • 5.4. COVID-19 Pandemic Impact on Industry

6. Global Meningitis Treatment Market Analysis and Forecast, by Causative Organism

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Causative Organism, 2020-2034
    • 6.3.1. Bacterial
    • 6.3.2. Viral
    • 6.3.3. Fungal
  • 6.4. Market Attractiveness, by Causative Organism

7. Global Meningitis Treatment Market Analysis and Forecast, by Treatment Type

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Treatment Type, 2020-2034
    • 7.3.1. Antibiotic Therapy
    • 7.3.2. Adjunctive Therapy
  • 7.4. Market Attractiveness, by Treatment Type

8. Global Meningitis Treatment Market Analysis and Forecast, by Vaccine Type

  • 8.1. Introduction and Definitions
  • 8.2. Key Findings/Developments
  • 8.3. Market Value Forecast, by Vaccine Type, 2020-2034
    • 8.3.1. Meningococcal Conjugate Vaccine
    • 8.3.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 8.3.3. Combination Vaccines
  • 8.4. Market Attractiveness, by Vaccine Type

9. Global Meningitis Treatment Market Analysis and Forecast, by Distribution Channel

  • 9.1. Introduction and Definitions
  • 9.2. Key Findings/Developments
  • 9.3. Market Value Forecast, by Distribution Channel, 2020-2034
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Attractiveness, by Distribution Channel

10. Global Meningitis Treatment Market Analysis and Forecast, by Region

  • 10.1. Key Findings
  • 10.2. Market Value Forecast, by Region, 2020-2034
    • 10.2.1. North America
    • 10.2.2. Europe
    • 10.2.3. Asia Pacific
    • 10.2.4. Latin America
    • 10.2.5. Middle East & Africa
  • 10.3. Market Attractiveness, by Region

11. North America Meningitis Treatment Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 11.2.1. Bacterial
    • 11.2.2. Viral
    • 11.2.3. Fungal
  • 11.3. Market Attractiveness, by Causative Organism
  • 11.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 11.4.1. Antibiotic Therapy
    • 11.4.2. Adjunctive Therapy
  • 11.5. Market Attractiveness, by Treatment Type
  • 11.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 11.6.1. Meningococcal Conjugate Vaccine
    • 11.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 11.6.3. Combination Vaccines
  • 11.7. Market Attractiveness, by Vaccine Type
  • 11.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 11.8.1. Hospital Pharmacy
    • 11.8.2. Retail Pharmacy
    • 11.8.3. Online Pharmacy
  • 11.9. Market Attractiveness, by Distribution Channel
  • 11.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 11.10.1. U.S.
    • 11.10.2. Canada
  • 11.11. Market Attractiveness Analysis
    • 11.11.1. By Causative Organism
    • 11.11.2. By Treatment Type
    • 11.11.3. By Vaccine Type
    • 11.11.4. By Distribution Channel
    • 11.11.5. By Country

12. Europe Meningitis Treatment Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 12.2.1. Bacterial
    • 12.2.2. Viral
    • 12.2.3. Fungal
  • 12.3. Market Attractiveness, by Causative Organism
  • 12.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 12.4.1. Antibiotic Therapy
    • 12.4.2. Adjunctive Therapy
  • 12.5. Market Attractiveness, by Treatment Type
  • 12.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 12.6.1. Meningococcal Conjugate Vaccine
    • 12.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 12.6.3. Combination Vaccines
  • 12.7. Market Attractiveness, by Vaccine Type
  • 12.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 12.8.1. Hospital Pharmacy
    • 12.8.2. Retail Pharmacy
    • 12.8.3. Online Pharmacy
  • 12.9. Market Attractiveness, by Distribution Channel
  • 12.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 12.10.1. Germany
    • 12.10.2. U.K.
    • 12.10.3. France
    • 12.10.4. Italy
    • 12.10.5. Spain
    • 12.10.6. Rest of Europe
  • 12.11. Market Attractiveness Analysis
    • 12.11.1. By Causative Organism
    • 12.11.2. By Treatment Type
    • 12.11.3. By Vaccine Type
    • 12.11.4. By Distribution Channel
    • 12.11.5. By Country/Sub-region

13. Asia Pacific Meningitis Treatment Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 13.2.1. Bacterial
    • 13.2.2. Viral
    • 13.2.3. Fungal
  • 13.3. Market Attractiveness, by Causative Organism
  • 13.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 13.4.1. Antibiotic Therapy
    • 13.4.2. Adjunctive Therapy
  • 13.5. Market Attractiveness, by Treatment Type
  • 13.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 13.6.1. Meningococcal Conjugate Vaccine
    • 13.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 13.6.3. Combination Vaccines
  • 13.7. Market Attractiveness, by Vaccine Type
  • 13.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 13.8.1. Hospital Pharmacy
    • 13.8.2. Retail Pharmacy
    • 13.8.3. Online Pharmacy
  • 13.9. Market Attractiveness, by Distribution Channel
  • 13.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 13.10.1. China
    • 13.10.2. Japan
    • 13.10.3. India
    • 13.10.4. Australia & New Zealand
    • 13.10.5. Rest of Asia Pacific
  • 13.11. Market Attractiveness Analysis
    • 13.11.1. By Causative Organism
    • 13.11.2. By Treatment Type
    • 13.11.3. By Vaccine Type
    • 13.11.4. By Distribution Channel
    • 13.11.5. By Country/Sub-region

14. Latin America Meningitis Treatment Market Analysis and Forecast

  • 14.1. Introduction
    • 14.1.1. Key Findings
  • 14.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 14.2.1. Bacterial
    • 14.2.2. Viral
    • 14.2.3. Fungal
  • 14.3. Market Attractiveness, by Causative Organism
  • 14.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 14.4.1. Antibiotic Therapy
    • 14.4.2. Adjunctive Therapy
  • 14.5. Market Attractiveness, by Treatment Type
  • 14.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 14.6.1. Meningococcal Conjugate Vaccine
    • 14.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 14.6.3. Combination Vaccines
  • 14.7. Market Attractiveness, by Vaccine Type
  • 14.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 14.8.1. Hospital Pharmacy
    • 14.8.2. Retail Pharmacy
    • 14.8.3. Online Pharmacy
  • 14.9. Market Attractiveness, by Distribution Channel
  • 14.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 14.10.1. Brazil
    • 14.10.2. Mexico
    • 14.10.3. Rest of Latin America
  • 14.11. Market Attractiveness Analysis
    • 14.11.1. By Causative Organism
    • 14.11.2. By Treatment Type
    • 14.11.3. By Vaccine Type
    • 14.11.4. By Distribution Channel
    • 14.11.5. By Country/Sub-region

15. Middle East & Africa Meningitis Treatment Market Analysis and Forecast

  • 15.1. Introduction
    • 15.1.1. Key Findings
  • 15.2. Market Value Forecast, by Causative Organism, 2020-2034
    • 15.2.1. Bacterial
    • 15.2.2. Viral
    • 15.2.3. Fungal
  • 15.3. Market Attractiveness, by Causative Organism
  • 15.4. Market Value Forecast, by Treatment Type, 2020-2034
    • 15.4.1. Antibiotic Therapy
    • 15.4.2. Adjunctive Therapy
  • 15.5. Market Attractiveness, by Treatment Type
  • 15.6. Market Value Forecast, by Vaccine Type, 2020-2034
    • 15.6.1. Meningococcal Conjugate Vaccine
    • 15.6.2. Meningococcal Polysaccharide Vaccine (MPSV4)
    • 15.6.3. Combination Vaccines
  • 15.7. Market Attractiveness, by Vaccine Type
  • 15.8. Market Value Forecast, by Distribution Channel, 2020-2034
    • 15.8.1. Hospital Pharmacy
    • 15.8.2. Retail Pharmacy
    • 15.8.3. Online Pharmacy
  • 15.9. Market Attractiveness, by Distribution Channel
  • 15.10. Market Value Forecast, by Country/Sub-region, 2020-2034
    • 15.10.1. GCC Countries
    • 15.10.2. South Africa
    • 15.10.3. Rest of Middle East & Africa
  • 15.11. Market Attractiveness Analysis
    • 15.11.1. By Causative Organism
    • 15.11.2. By Treatment Type
    • 15.11.3. By Vaccine Type
    • 15.11.4. By Distribution Channel
    • 15.11.5. By Country/Sub-region

16. Competition Landscape

  • 16.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 16.2. Market Share Analysis, by Company (2023)
  • 16.3. Company Profiles
    • 16.3.1. Bio-med (P) Ltd.
      • 16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.1.2. Product Portfolio
      • 16.3.1.3. Financial Overview
      • 16.3.1.4. SWOT Analysis
      • 16.3.1.5. Strategic Overview
    • 16.3.2. Novartis AG
      • 16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.2.2. Product Portfolio
      • 16.3.2.3. Financial Overview
      • 16.3.2.4. SWOT Analysis
      • 16.3.2.5. Strategic Overview
    • 16.3.3. Nuron Biotech, Inc.
      • 16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.3.2. Product Portfolio
      • 16.3.3.3. Financial Overview
      • 16.3.3.4. SWOT Analysis
      • 16.3.3.5. Strategic Overview
    • 16.3.4. Pfizer Inc.
      • 16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.4.2. Product Portfolio
      • 16.3.4.3. Financial Overview
      • 16.3.4.4. SWOT Analysis
      • 16.3.4.5. Strategic Overview
    • 16.3.5. Baxter International Inc.
      • 16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.5.2. Product Portfolio
      • 16.3.5.3. Financial Overview
      • 16.3.5.4. SWOT Analysis
      • 16.3.5.5. Strategic Overview
    • 16.3.6. Merck & Co. Inc.
      • 16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.6.2. Product Portfolio
      • 16.3.6.3. Financial Overview
      • 16.3.6.4. SWOT Analysis
      • 16.3.6.5. Strategic Overview
    • 16.3.7. Sanofi S.A.
      • 16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.7.2. Product Portfolio
      • 16.3.7.3. Financial Overview
      • 16.3.7.4. SWOT Analysis
      • 16.3.7.5. Strategic Overview
    • 16.3.8. GSK PLC
      • 16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.8.2. Product Portfolio
      • 16.3.8.3. Financial Overview
      • 16.3.8.4. SWOT Analysis
      • 16.3.8.5. Strategic Overview
    • 16.3.9. F. Hoffmann-Roche AG
      • 16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.9.2. Product Portfolio
      • 16.3.9.3. Financial Overview
      • 16.3.9.4. SWOT Analysis
      • 16.3.9.5. Strategic Overview
    • 16.3.10. Athlone Laboratories Limited
      • 16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.10.2. Product Portfolio
      • 16.3.10.3. Financial Overview
      • 16.3.10.4. SWOT Analysis
      • 16.3.10.5. Strategic Overview
    • 16.3.11. Wockhardt
      • 16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 16.3.11.2. Product Portfolio
      • 16.3.11.3. Financial Overview
      • 16.3.11.4. SWOT Analysis
      • 16.3.11.5. Strategic Overview
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦